Evaluating the potential bioactivity of a novel compound ER1626

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Wang, Lijun ^a   Zeng, Yanyan ^a   Wang, Tianling ^b   Liu, Hongyi ^a   Xiao, Hong ^a   Xiang, Hua ^b  

^a THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 [3 (DIETHYLLAMINO)PROPOXY]PHENYL] 5H INDENO[1,2 C]ISOQUINOLINE 5,11(6H) DIONEIS; ER 1626; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; EMBRYO; ENDOMETRIUM CANCER; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDENES; ISOQUINOLINES; KETONES; MCF-7 CELLS; MOLECULAR STRUCTURE; QUINOLONES; RECEPTORS, ESTROGEN; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84899936311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086509     Document Type: Article

References (41)

1. American cancer society (2012) Cancer facts & figure 2012. Atlanta: American cancer society.
2. Dent SF, Gaspo R, Kissner M, Pritchard KI (2011) Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 126: 295-310.
3. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047-1059.
4. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285. (Pubitemid 32108534)
5. Balfe PJ, McCann AH, Welch HM, Kerin MJ (2004) Estrogen receptor beta and breast cancer. Eur J Surg Oncol 30: 1043-1050. (Pubitemid 40267807)
6. Nilsson S, Gustafsson JA (2000) Estrogen receptor transcription and transactivation: Basic aspects of estrogen action. Breast Cancer Res 2: 360-366.
7. Leygue E, Dotzlaw H, Watson PH, Murphy LC (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 58: 3197-3201. (Pubitemid 28371051)
8. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
9. Birkhäuser M (2012) Selective estrogen receptor modulators for prevention and treatment of postmenopausal osteoporosis. Ther Umsch 69: 163-172.
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388. (Pubitemid 28439961)
11. Brown K (2009) Is tamoxifen a genotoxic carcinogen in women? Mutagenesis 24: 391-404.
12. González Martín A, de la Cruz S, Márquez R (2010) Adjuvant endocrine therapy in premenopausal women with breast cancer. Breast Cancer Res Treat 123: 43-47.
13. Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, et al. (2011) The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol 126: 78-86.
14. Vogel VG, Costantino JP, Wickerham DL, Cronin WM,Cecchini RS, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295: 2727-2741.
15. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645. (Pubitemid 29384151)
16. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125-137. (Pubitemid 44050394)
17. Stefanick ML (2006) Risk-benefit profiles of raloxifene for women. N Engl J Med 355: 190-192.
18. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281: 2189-2197. (Pubitemid 29275701)
19. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes : the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741.
20. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
21. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W (1998) Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111: 1853-1865. (Pubitemid 28370530)
22. Kevil CG, Payne DK, Mire E, Alexander JS (1998) Vascular permeability factor/vascular endothelial growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 273: 15099-15103. (Pubitemid 28272806)
23. Dimmeler S, Dernbach E, Zeiher AM (2000) Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 477: 258-262. (Pubitemid 30450177)
24. Minchenko A, Bauer T, Salceda S, Caro J (1994) Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71: 374-379. (Pubitemid 24310017)
25. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, et al. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
26. Hua X, Tianlin W, Xiao H, Qidong Y, yao Y, et al. (2011) Indenoisoquinolinone derivantives, manufacturing method and medical use thereof. International Patent WO/2011/047515.
27. Hua X, Tianlin W, Xiao H, Qidong Y, yao Y, et al. (2010) Indeno-isoquinoline derivantives, its manufacturing method and medicine usage. China Patent CN 101693688 A.
28. Dalenc F, Giamarchi C, Petit M, Poirot M, Favre G (2005) Farnesyl-transferase inhibitor R115, 777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res 7: R1159-1167.
29. Guthrie N, Gapor A, Chambers AF, Carroll KK (1997) Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 127: 544S-548S. (Pubitemid 27120013)
30. Wan Z, Musa MA, Joseph P, Cooperwood JS (2013) Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents. Mini Rev Med Chem 13: 1381-1388.
31. Musa MA, Zhou A, Sadik OA (2011) Synthesis and antiproliferative activity of new coumarin-based benzopyranone derivatives against human tumor cell lines. Med Chem 7: 112-120.
32. Morris AD, Léonce S, Guilbaud N, Tucker GC, Pérez V (1997) Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth in vivo. Anticancer Drugs 8: 746-755. (Pubitemid 27451816)
33. Hu K, Zhong G, He F (2005) Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 15: 537-541. (Pubitemid 40705553)
34. Pinkerton JV, Goldstein SR (2010) Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause17: 642-653.
35. Heldring N, Pike A, Andersson S, Matthews J, Cheng G (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87: 905-931. (Pubitemid 47084672)
36. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ (2008) Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 109: 241-250. (Pubitemid 351644839)
37. Mendoza RA, Enriquez MI, Mejia SM, Moody EE, Thordarson G (2011) Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells. J Endocrinol 208: 1-9.
38. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, et al. (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64: 423-428. (Pubitemid 38114127)
39. Applanat MP, Buteau-Lozano H, Herve MA, Corpet A (2008) Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol 617: 437-444.
40. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
41. Fima E, Shtutman M, Libros P, Missel A, Shahaf G, et al. (2001) PKCeta enhances cell cycle progression, the expression of G1 cyclin and p21 in MCF-7 cells. Oncogene 20: 6794-6804. (Pubitemid 33020608)